Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 2845 • 2014 ACR/ARHP Annual Meeting
Altered Plasticity of Inflammatory CD4 T Cells Contributing to Th17 Shift in Rheumatoid Arthritis
Jan Leipe, Fausto Pirronello, Simon Hermann, Matthias Witt, Hendrik Schulze-Koops and Alla Skapenko, Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany
Background/Purpose Whereas T helper (Th) cell subsets were previously regarded as irreversibly differentiated endpoints, evidence suggests that Th cell differentiation is a plastic process in…
Abstract Number: 1845 • 2014 ACR/ARHP Annual Meeting
Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial
Gerd Burmester¹, William Rigby², Ronald F. van Vollenhoven³, Jonathan Kay⁴, Andrea Rubbert-Roth⁵, Ricardo Blanco⁶, Ariella Kelman⁷, Sophie Dimonaco⁸ and Nina Mitchell⁸, ¹Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Karolinska Institute, Stockholm, Sweden, ⁴UMass Memorial Medical Center, Worcester, MA, ⁵University of Cologne, Cologne, Germany, ⁶Hospital Marques de Valdecilla, Santander, Spain, ⁷Genentech, South San Francisco, CA, ⁸Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Treatment with tocilizumab (TCZ) in combination with MTX or as monotherapy (Mono) in MTX-naive patients (pts) with early RA resulted in improved signs and…
Abstract Number: 395 • 2014 ACR/ARHP Annual Meeting
Could Osteoprotegerin and TNF-Related Apoptosis-Inducing Ligand Assessments Help Us to Manage Early Rheumatoid Arthritis? Results from the Espoir Cohort
Rachel Audo¹, Claire I. Daien², Laura Papon¹, Cédric Lukas³, O Vittecoq⁴, B Combe⁵ and Jacques Morel⁶, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rouen University Hospital & Inserm U905, Rouen, France, ⁵Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁶Department of Rheumatology, Hôpital Lapeyronie, Montpellier, France
Background/Purpose : TNF-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF familly. Its soluble receptor Osteoprotegerin (OPG) also inhibits Receptor activator of nuclear…
Abstract Number: 2515 • 2014 ACR/ARHP Annual Meeting
Serum Survivin in Early Rheumatoid Arthritis
Adrian Levitsky¹, Malin Erlandsson², Maria Bokarewa² and Ronald F. van Vollenhoven³, ¹The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, ²Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden
Background/Purpose: The proto-oncogene survivin regulates cell division and inhibits apoptosis. Elevated levels may be found in patients with rheumatoid arthritis (RA) and their presence has…
Abstract Number: 1738 • 2014 ACR/ARHP Annual Meeting
Prominent Role of CCR6+ T Helper Cells in the Pathogenesis of ACPA+ Patients with Early RA
Sandra M.J. Paulissen¹, Jan Piet van Hamburg², Nadine Davelaar², Heleen Vroman³, Johanna MW Hazes⁴, P.H.P. de Jong⁵ and Erik Lubberts², ¹Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands, ²Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Rheumatology and Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ⁵Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands
Background/Purpose: Presence of serum anti-citrullinated protein antibodies (ACPAs) in patients with rheumatoid arthritis (RA) predicts worse disease course and a more erosive disease. In the…
Abstract Number: 394 • 2014 ACR/ARHP Annual Meeting
Very Low or High Body Mass Index Negatively Affects patients’ Ability to Achieve Sustained Remission in Early RA in a Multicenter Canadian Cohort
Susan M. Goodman¹, Yan Ma², Wei Zhang³, Elizabeth Schulman⁴, Janet E. Pope⁵, Carol Hitchon⁶, Susan J. Bartlett⁷, Boulos Haraoui⁸, Daming Lin⁹, Gilles Boire¹⁰, Diane Tin¹¹, J. Carter Thorne¹², Shahin Jamal¹³, Edward C. Keystone¹⁴ and Vivian P. Bykerk^1,15, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Research - Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ³Healthcare Research Institute, Hospital for Special Surgery, New York, NY, ⁴Rheumatology, New York Presbyterian - Cornell Campus - HSS, New York, NY, ⁵St Joseph Health Care, London, ON, Canada, ⁶Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁷Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ⁸University of Montreal Hospital Centre, Montreal, QC, Canada, ⁹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Southlake Regional Health Centre, Newmarket, Newmarket, ON, Canada, ¹³Vancouver General Hospital, Vancouver, BC, Canada, ¹⁴Medicine, University of Toronto, Toronto, ON, Canada, ¹⁵Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: To determine if patients with a very low body mass index (BMI) (
Abstract Number: 2503 • 2014 ACR/ARHP Annual Meeting
Early Response to Full-Dose Etanercept-Plus-Methotrexate Induction Therapy Predicts Sustained Remission with Reduced-Dose Combination Therapy in Early Rheumatoid Arthritis Patients
Paul Emery¹, Ronald Pedersen², Jack Bukowski³ and Lisa Marshall⁴, ¹NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom, ²Specialty Care, Pfizer Inc, Collegeville, PA, ³Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose: In early rheumatoid arthritis (RA), achievement of clinical remission and low disease activity (LDA) limits joint damage and disability.1 Anti-TNF agents are effective in…
Abstract Number: 1527 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: An Indirect Comparison
Laura Sawyer¹, Stacey Chang¹, Alex Diamantopoulos² and Fred Dejonckheere³, ¹Symmetron Limited, London, United Kingdom, ²Symmetron Limited, Herts, United Kingdom, ³F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: To date, no head-to-head trials have been conducted comparing the efficacy of biologic treatments for early active rheumatoid arthritis (ERA). Here, we evaluated the…
Abstract Number: 392 • 2014 ACR/ARHP Annual Meeting
Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis – Do Free Fatty Acids Play a Role?
Man Wai Tang¹, Frieda A. Koopman², Jan P.M. Visscher², Marjolein J.H. de Hair², Danielle M. Gerlag^2,3 and Paul P. Tak^2,4, ¹Division of Clinical Immunology and Rheumatology & Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³GlaxoSmithKline, Cambridge, United Kingdom, ⁴University of Cambridge, Cambridge and GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with several neuroendocrine hormones and metabolic peptides. The crosstalk between the hormones and the immune…
Abstract Number: 2485 • 2014 ACR/ARHP Annual Meeting
Predictors of Drug-Free Remission Following Treatment with Abatacept (in Combination with Methotrexate or as Monotherapy) in Early Rheumatoid Arthritis
P Emery¹, Gerd Burmester², Vivian P. Bykerk³, B Combe⁴, Daniel E. Furst⁵, E Barre⁶, C S Karyekar⁷, D Wong⁷ and T W J Huizinga⁸, ¹University of Leeds, Leeds, United Kingdom, ²Charité – University Medicine Berlin, Berlin, Germany, ³Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁴Monpellier University Hospital, Montpellier, France, ⁵University of California at Los Angeles, Los Angeles, CA, ⁶Bristol-Myers Squibb, Braine-L’Alleud, Belgium, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the Phase IIIb, randomized, double-blind, active-controlled AVERT study, abatacept (ABA) + MTX and ABA monotherapy induced protocol-defined DAS remission (DAS28 [CRP]
Abstract Number: 1521 • 2014 ACR/ARHP Annual Meeting
Sustained Improvements in Magnetic Resonance Imaging Outcomes with Abatacept Following the Withdrawal of All Treatment in Patients with Early Rheumatoid Arthritis
C Peterfy¹, Gerd Burmester², Vivian P. Bykerk³, B G Combe⁴, J C DiCarlo¹, Daniel E. Furst⁵, T W J Huizinga⁶, C S Karyekar⁷, D Wong⁷, Philip G. Conaghan⁸ and P Emery⁹, ¹Spire Sciences, Inc., Boca Raton, FL, ²Charité – University Medicine Berlin, Berlin, Germany, ³Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁴Hôpital Lapeyronie, Montpellier, France, ⁵University of California at Los Angeles, Los Angeles, CA, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁹University of Leeds, Leeds, United Kingdom
Background/Purpose: Biologic treatment can lead to improved clinical outcomes in early RA. In the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) study, abatacept (ABA) +…
Abstract Number: 388 • 2014 ACR/ARHP Annual Meeting
Soluble TREM-1 Is a Biomarker of Anti-CCP-Positive, DMARD-Naive Early Rheumatoid Arthritis
Shachaf Ofer-Shiber¹, Elisheva Pokroy-Shapira², Yair Molad^3,4, Shirly Oren², Hagit Shay-Aharoni² and Ilan Babai⁵, ¹Department of Internal Medicine H, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ²Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ³Rheumatology Unit, Rabin Medical Center, Beilinson Hospital and Sackler Faculty of Medicine, Tel Aviv University, Petah Teqva, Israel, ⁴Laboratory of Inflammation Research, Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petach Tikva, Israel, ⁵Laboratory of Clinical Immunology, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
Background/Purpose : Triggering receptor expressed on myeloid cells-1 (TREM-1) is a cell-surface receptor, expressed mainly on monocytes and neutrophils and involved in amplification of the inflammatory…
Abstract Number: 2472 • 2014 ACR/ARHP Annual Meeting
The First, Multicenter, Double-Blind, Randomized, Parallel-Group Study of Certolizumab Pegol in Early Rheumatoid Arthritis Demonstrates Inhibition of Joint Damage Progression
Tatsuya Atsumi¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Hisashi Yamanaka⁴, Naoki Ishiguro⁵, Yoshiya Tanaka⁶, Katsumi Eguchi⁷, Akira Watanabe⁸, Hideki Origasa⁹, Toshiharu Shoji¹⁰, Osamu Togo¹¹, Toshiyuki Okada¹², Désirée M. van der Heijde¹³, Nobuyuki Miyasaka¹⁴ and Takao Koike^15,16, ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Kitakyushu, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Department of orthopedics, Nagoya University Graduate School and Faculty of Medicine, Nagoya, Japan, ⁶The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁷Department of Rheumatology, Sasebo City General Hospital, Nagasaki, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, School of Medicine, Tohoku University, Tokyo, Japan, ⁹Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Japan, ¹⁰Department of Clinical Research and Development, UCB Pharma, Tokyo, Japan, ¹¹Biometrics Group, UCB Pharma, Tokyo, Japan, ¹²Astellas Pharma Inc, Tokyo, Japan, ¹³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁴Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹⁵NTT Sapporo Medical Center, Sapporo, Japan, ¹⁶Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose The efficacy and safety of certolizumab pegol (CZP)+methotrexate (MTX) therapy compared to MTX alone, in Japanese MTX-naïve early rheumatoid arthritis (RA) patients (pts) with…
Abstract Number: 1411 • 2014 ACR/ARHP Annual Meeting
Psychological Distress over Time in Early Rheumatoid Arthritis: Results from a Longitudinal Study in an Early Arthritis Cohort
Bernard Combe¹, Nathalie Rincheval², René-Marc Flipo³, Philipe M. Goupille⁴, Jean-Pierre Daurès² and JP Boulenger⁵, ¹Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ²Institut Universitaire de Recherche Clinique, Montpellier, France, ³Rheumatology, Hopital R Salengro CHRU, Lille CEDEX, France, ⁴Rheumatology, Hopital Trousseau, Tours, France, ⁵CHRU Montpellier I University, La Colombiere Hospital, Montpellier, France
Background/Purpose Rheumatoid arthritis (RA) is a chronic disease with frequent psychological comorbidities, of which depression and anxiety are 2 common manifestations. We aimed to identify…
Abstract Number: 362 • 2014 ACR/ARHP Annual Meeting
14-3-3η Early RA Biomarkers: Does Seronegative RA Exist?
Dirkjan van Schaardenburg¹, Walter P. Maksymowych², Maarten Boers³, Samina Turk⁴, Mairead Murphy⁵ and Anthony Marotta⁶, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Deapartment of Epidemiology and Biostatistics, Jan van Breemen Research Institute/Reade, Amsterdam, Netherlands, ⁴Reade, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp., North Vancouver, BC, Canada, ⁶1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose RF and ACPA are used for early diagnosis and in prediction models for the risk of RA development in arthralgia patients. There remains a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].